Evidence map›Paper›PMID 34824121›Full record

ArticleBMJ open2021

Cross-sectional study comparing cognitive function in treatment responsive versus treatment non-responsive schizophrenia: evidence from the STRATA study.

Edward Millgate, Eugenia Kravariti, Alice Egerton, Oliver D Howes, Robin M Murray, Laura Kassoumeri, Jacek Donocik, Shôn Lewis, Richard Drake, Stephen Lawrie and 7 more

Abstract read
In one paragraph

Article in BMJ open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Improving outcome of treatment-resistant schizophrenia: effects of cognitive remediation therapy.European archives of psychiatry and clinical neuroscience · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Edward MillgateDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.ORCID 0000-0001-5424-8261
Eugenia KravaritiDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Alice EgertonDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Oliver D HowesDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Robin M MurrayDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Laura KassoumeriDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Jacek DonocikDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Shôn LewisDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Richard DrakeDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.ORCID 0000-0003-0220-4835
Stephen LawriePsychiatry, The University of Edinburgh Division of Psychiatry, Edinburgh, UK.
Anna MurphyDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Tracy CollierDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK.
Jane LeesDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
Charlotte Stockton-PowdrellDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
James WaltersMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
Bill DeakinDivision of Psychology and Mental Health, The University of Manchester, Manchester, UK.
James MacCabeDepartment of Psychosis Studies, King's College London Institute of Psychiatry Psychology and Neuroscience, London, UK james.maccabe@kcl.ac.uk.

Funding

Medical Research Council MR/L010305/1Medical Research Council MR/L011794Medical Research Council MR/L011794/1
6 · The paper itself

Abstract

background70%-84% of individuals with antipsychotic treatment resistance show non-response from the first episode. Emerging cross-sectional evidence comparing cognitive profiles in treatment resistant schizophrenia to treatment-responsive schizophrenia has indicated that verbal memory and language functions may be more impaired in treatment resistance. We sought to confirm this finding by comparing cognitive performance between antipsychotic non-responders (NR) and responders (R) using a brief cognitive battery for schizophrenia, with a primary focus on verbal tasks compared against other measures of cognition.

designCross-sectional.

settingThis cross-sectional study recruited antipsychotic treatment R and antipsychotic NR across four UK sites. Cognitive performance was assessed using the Brief Assessment of Cognition in Schizophrenia (BACS).

participantsOne hundred and six participants aged 18-65 years with a diagnosis of schizophrenia or schizophreniform disorder were recruited according to their treatment response, with 52 NR and 54 R cases. OUTCOMES: Composite and subscale scores of cognitive performance on the BACS. Group (R vs NR) differences in cognitive scores were investigated using univariable and multivariable linear regressions adjusted for age, gender and illness duration.

resultsUnivariable regression models observed no significant differences between R and NR groups on any measure of the BACS, including verbal memory (ß=-1.99, 95% CI -6.63 to 2.66, p=0.398) and verbal fluency (ß=1.23, 95% CI -2.46 to 4.91, p=0.510). This pattern of findings was consistent in multivariable models.

conclusionsThe lack of group difference in cognition in our sample is likely due to a lack of clinical distinction between our groups. Future investigations should aim to use machine learning methods using longitudinal first episode samples to identify responder subtypes within schizophrenia, and how cognitive factors may interact within this. TRAIL REGISTRATION NUMBER: REC: 15/LO/0038.

Indexed as

Antipsychotic AgentsCognition DisordersSchizophreniaCognitionCross-Sectional StudiesHumansNeuropsychological TestsSchizophrenia, Treatment-ResistantAntipsychotic Agentsadult psychiatrypsychiatryschizophrenia & psychotic disorders

Identifiers

PMID34824121
PMCPMC8627394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.